Usefulness of the serum galactomannan assay for early response assessment and treatment stratifications of invasive aspergillosis

Current Fungal Infection Reports

Volumn 6, Issue 3, 2012, Pages 198-205

  Seeber, Katharina ^a   Duettmann, Wiebke ^a   Krause, Robert ^a   Hoenigl, Martin ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Antifungal therapy; Antifungals; Aspergillus; Early response assessment; Early treatment stratifications; Galactomannan; Galactomannan enzyme immune assay; Hematologialc malignancy; Immunocompromised patients; Invasive aspergillosis; Neutropenia; Outcome assessment; Surrogate marker; Therapeutic monitoring; Therapy end point

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN; GALACTOMANNAN; INFLIXIMAB; PIPERACILLIN PLUS TAZOBACTAM; VORICONAZOLE;

ACUTE LEUKEMIA; ALTERNARIA; ARTICLE; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CANCER CHEMOTHERAPY; CELL WALL; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HISTOPLASMA CAPSULATUM; HUMAN; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; NEUTROPENIA; PAECILOMYCES; PENICILLIUM; PROGNOSIS; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 84869134182     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-012-0099-5     Document Type: Article

References (55)

1. Segal BH. Aspergillosis. N Engl J Med. 2009;360(18):1870-84. Epub 2009/05/01.
2. Hoenigl M, Strenger V, BuzinaW, et al. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. J Antimicrob Chemother. 2012. Epub 2012/05/09.
3. Hoenigl M, Valentin T, Salzer HJ, et al. Underestimating the real burden of invasive fungal infections in hematopoietic stem cell transplant recipients? Clin Infect Dis Offic Pub Infect Dis Soc Am. 2010;51(2):253-4. author reply 4-5. Epub 2010/06/22.
4. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: An autopsy study over a 15-year period (1989-2003). Haematologica. 2006;91(7):986-9. Epub 2006/06/08.
5. Mikkonen KS, Rita H, Helen H, et al. Effect of polysaccharide structure on mechanical and thermal properties of galactomannanbased films. Biomacromolecules. 2007;8(10):3198-205. Epub 2007/09/22.
6. Reid GG, Edwards JG, Marshall GE, et al. Hydrogen peroxide induces microvilli on human retinal pigment epithelial cells in culture. Cell Biol Int. 1995;19(2):91-101. Epub 1995/02/01.
7. Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: Clinical and research implications. Clin Infect Dis Offic Pub Infect Dis Soc Am. 2008;46(9):1412-22. Epub 2008/04/19.
8. Furfaro E, Mikulska M, Miletich F, Viscoli C. Galactomannan: Testing the same sample twice? Transplant infectious disease: An official journal of the Transplantation Society. 2012. Epub 2012/04/11.
9. Becker MJ, Lugtenburg EJ, Cornelissen JJ, et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol. 2003;121 (3):448-57. Epub 2003/04/29.
10. Maertens J, Verhaegen J, Demuynck H, et al. Autopsycontrolled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol. 1999;37(10):3223-8. Epub 1999/09/17.
11. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol Offic J Am Soc Clin Oncol. 2002;20(7):1898-906. Epub 2002/03/29.
12. Maertens JA, Klont R, Masson C, et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis Offic Pub Infect Dis Soc Am. 2007;44(10):1329-36. Epub 2007/04/20.
13. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, et al. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev. 2008;(4):CD007394. Epub 2008/10/10.
14. Hoenigl M, Salzer HJ, Raggam RB, et al. Impact of galactomannan testing on the prevalence of invasive aspergillosis in patients with hematological malignancies. Med Mycol Offic Pub Intern Soc Hum Anim Mycol. 2012;50(3):266-9. Epub 2011/09/ 13. The paper shows that GM screening has a significant impact on IFI epidemiology.
15. Hoenigl M, Zollner-Schwetz I, Sill H, et al. Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies. Mycoses. 2011;54 (5):454-9. Epub 2010/04/22.
16. Husain S, Clancy CJ, Nguyen MH, et al. Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin Vaccine Immunol. 2008;15(12):1760-3. Epub 2008/10/11.
17. Luong ML, Filion C, Labbe AC, et al. Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies. Diagn Microbiol Infect Dis. 2010;68(2):132-9. Epub 2010/09/18.
18. Patterson TF. Risk stratification for invasive aspergillosis: Early assessment of host susceptibility. Med Mycol Offic Pub Intern Soc Hum Anim Mycol. 2009;47 Suppl 1:S255-60. Epub 2009/03/03.
19. Aubry A, Porcher R, Bottero J, et al. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol. 2006;44(2):389-94. Epub 2006/ 02/04.
20. Singh N, Obman A, Husain S, et al. Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: Clinical implications based on achievable concentrations in serum. Antimicrob Agents Chemother. 2004;48(6):1989-92. Epub 2004/05/ 25.
21. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis Offic Pub Infect Dis Soc Am. 2005;40(12):1762-9. Epub 2005/05/24.
22. Hoenigl M, Raggam RB, Salzer HJ, et al. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents. 2012;39 (6):510-3. Epub 2012/04/07.
23. McCulloch E, Ramage G, Rajendran R, et al. Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis. J Clin Pathol. 2012;65(1):83-6. Epub 2011/11/04.
24. Klont RR, Mennink-Kersten MA, Ruegebrink D, et al. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis Offic Pub Infect Dis Soc Am. 2006;43(3):e23-5. Epub 2006/ 06/29.
25. Clancy CJ, Jaber RA, Leather HL, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol. 2007;45 (6):1759-65. Epub 2007/04/13.
26. del Palacio A, Alhambra A, Cuetara MS, Ponton J. [Early diagnosis of invasive fungal infections caused by Aspergillus and other emerging mycelial fungi]. Revista iberoamericana de micologia. 2007;24(3):187-97. Epub 2007/09/19.
27. Cummings JR, Jamison GR, Boudreaux JW, et al. Cross-reactivity of non-Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay. Diagn Microbiol Infect Dis. 2007;59(1):113-5. Epub 2007/07/31.
28. Lopes da Silva R, Ribeiro P, Abreu N, et al. Early diagnosis of invasive aspergillosis in neutropenic patients. Comparison between serum galactomannan and polymerase chain reaction. Clin Med Ins Oncol. 2010;4:81-8.
29. Agrawal S, Hope W, Sinko J, Kibbler C. Optimizing management of invasive mould diseases. J Antimicrob Chemother. 2011;66 Suppl 1:i45-53. Epub 2011/01/05.
30. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother. 2002;46(1):12-23. Epub 2001/12/26.
31. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: Synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis. 2003;187(12):1834-43. Epub 2003/06/07.
32. Vallor AC, Kirkpatrick WR, Najvar LK, et al. Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture. Antimicrob Agents Chemother. 2008;52 (7):2593-8. Epub 2008/05/14.
33. Becker MJ, de Marie S, Willemse D, et al. Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model. J Clin Microbiol. 2000;38(4):1434-8. Epub 2000/04/04.
34. Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance. J Infect Dis. 2004;190(3):641-9. Epub 2004/07/10.
35. Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: Increasing antigenemia is associated with progressive disease. Clin Infect Dis Offic Pub Infect Dis Soc Am. 2002;34(7):939-43. Epub 2002/03/07. The first study to report an association between GMI and IA progression.
36. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis Offic Pub Infect Dis Soc Am. 2008;46 (3):327-60. Epub 2008/01/08.
37. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: MycosesStudy Group andEuropeanOrganizationforResearch and Treatment of Cancer consensus criteria. Clin Infect Dis Offic Pub Infect Dis Soc Am. 2008;47(5):674-83. Epub 2008/07/22.
38. Anaissie EJ. Trial design for mold-active agents: Time to break the mold-aspergillosis in neutropenic adults. Clin Infect Dis Offic Pub Infect Dis Soc Am. 2007;44(10):1298-306. Epub 2007/04/20.
39. Wirk B, Wingard Jr. Assessing responses to treatment of opportunistic mycoses and salvage strategies. Curr Infect Dis Rep. 2011;13(6):492-503. Epub 2011/09/29.
40. Woods G, Miceli MH, Grazziutti ML, et al. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: A study of 56 patients with hematologic cancer. Cancer. 2007;110(4):830-4. Epub 2007/07/04. The second study that correlated GMI with outcome in IA.
41. Marr KA. Aspergillus galactomannan index: A surrogate end point to assess outcome of therapy? Clin Infect Dis Offic Pub Infect Dis Soc Am. 2008;46(9):1423-5. Epub 2008/04/19.
42. Park SH, Choi SM, Lee DG, et al. Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients. Mycoses. 2011;54(6):523-30. Epub 2011/05/25. Study correlating sGMI kinetics after 6 and 12 weeks with outcome of IA.
43. Maertens J, Buve K, Theunissen K, et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer. 2009;115 (2):355-62. Epub 2009/01/01. The first study to evaluate GM as surrogate endpoint at week 6.
44. Chai LY, Kullberg BJ, Johnson EM, et al. Early Serum Galactomannan Trend as a Predictor of Outcome in Invasive Aspergillosis. Journal of clinical microbiology. 2012. Epub 2012/05/04. Groundbreaking study that evaluated GMI as predictor of outcome in IA patients with positive and negative baseline GMI.
45. Nouer SA, Nucci M, Kumar NS, et al. Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: Proposal for a new definition. Clin Infect Dis Offic Pub Infect Dis Soc Am. 2011;53(7):671-6. Epub 2011/08/19. Groundbreaking study that proposed a new definition for treatment response based on GMI values only.
46. Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. Journal of clinical microbiology. 2010;48 (4):1255-60. Epub 2010/02/12. Study evaluated GMI between baseline and week 1for prognosis pf IA.
47. Bergeron A, Porcher R, Menotti J, et al. Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients. Journal of clinical microbiology. 2012;50(3):823-30. Epub 2011/12/16. Study compared different clinical and biological markers for prediction of IA outcome.
48. Wu CJ, Lee HC, Lo HJ, Ko WC. Resolution of galactomannan antigenemia in a patient receiving oral voriconazole for chronic necrotizing pulmonary aspergillosis. Diagn Microbiol Infect Dis. 2011;70(4):528-30. Epub 2011/06/11.
49. Valentin T, Neumeister P, Pichler M, et al. Disseminated Geosmithia argillacea infection in a patient with gastrointestinal GvHD. Bone Marrow Transplant. 2012;47(5):734-6. Epub 2011/ 07/26.
50. Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: A tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008;177 (1):27-34. Epub 2007/09/22.
51. Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: A 6-year survey. Clin Infect Dis Offic Pub Infect Dis Soc Am. 2006;43(5):577-84. Epub 2006/08/04.
52. Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: Results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis Offic Pub Infect Dis Soc Am. 2007;45(9):1161-70. Epub 2007/10/06.
53. Cordonnier C, Botterel F, Ben Amor R, et al. Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin Microbiol Infect. 2009;15(1):81-6.
54. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001;344 (14):1099-100. Epub 2001/04/09.
55. Maschmeyer G, Beinert T, Buchheidt D, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer. 2009;45(14):2462-72. Epub 2009/05/27.